Form 4: Pacira BioSciences Executive Kristen Williams Reports Stock Transactions
SEC Form 4 Filing
Kristen Williams, Chief Administrative Officer of Pacira BioSciences, reports the acquisition and disposal of company stock, including transactions made under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Kristen Williams, Chief Administrative Officer of Pacira BioSciences, filed a Form 4 detailing changes in beneficial ownership.
- On June 12, 2024, Williams acquired 54,300 shares of common stock, with the price noted as $0.
- These shares represent restricted stock units that vest in four equal annual installments starting June 3, 2025, contingent upon continuous service with the issuer.
- On June 13, 2024, Williams disposed of 7,452 shares of common stock at a price of $28.38 per share.
- Following these transactions, Williams beneficially owns 102,912 shares of Pacira BioSciences common stock.
- The sales were executed under a Rule 10b5-1 trading plan.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transactions include both acquisition and disposal of shares, with the sale occurring under a pre-arranged trading plan. It doesn't strongly indicate positive or negative sentiment.
Industry Context
Executive stock transactions are routinely monitored by investors to gauge management's perspective on the company's prospects. Transactions under 10b5-1 plans are less indicative of current sentiment as they are pre-arranged.
Comparison to Industry Standards
- Executive stock transactions are common and are reported across the pharmaceutical and biotechnology industries.
- Companies like Amgen, Gilead Sciences, and Biogen also have executives who regularly report stock transactions.
- The use of Rule 10b5-1 trading plans is a standard practice to avoid accusations of insider trading.
Stakeholder Impact
- Shareholders may monitor these transactions for insights into management's view of the company's value.
- The transactions themselves are unlikely to have a significant impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 06/03/2025 | First vesting date for restricted stock units. |
| 06/12/2024 | Acquisition of 54,300 shares of common stock. |
| 06/13/2024 | Sale of 7,452 shares of common stock at $28.38 per share. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.